Commentary: June 14th: Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond -- Bast and Mills, 10.1200/JCO.2010.28.5791 -- Journal of Clinical Oncology

Note: links directly to pdf article/overview of ovarian cancer treatments including PARPs, Avastin, Tamoxifen, AZ6244..

"If we are to progress at an optimal pace, accrual of a larger fraction of patients to clinical trials will be essential, requiring referral of ovarian cancer patients to major centers at first recurrence of their disease."